Asahi deal not enough to save RaQualia from wider losses

19 Nov 2013

The pharma division of the diversified Japanese chemicals and materials group Asahi Kasei has signed a collaborative research agreement with RaQualia Pharma aimed at the discovery of new therapeutics against a specific (but unidentified) ion channel target.

While the new tie-up gave a much-needed boost to RaQualia's stock price after a paucity of licensing deals this year,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

18 Jun 2025

• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

UCB Follows Fellow European Pharmas With Major US Investment

13 Jun 2025

• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

Sanofi Revels In More Positive Rilzabrutinib Data

12 Jun 2025

• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

12 Jun 2025

• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

ASCO: Pushing The Frontiers Of ADCs

19 Jun 2025

• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.